The Beneluxa collaboration has issued a joint statement with the Nordic Pharmaceutical Forum. The statement reiterates the importance of cost effectiveness in the assessment of value for medicines as well as the challenges with the lack of availability of robust clinical evidence for decision makers in a timely manner. Joint working on these problems is at the heart of this collaboration.